Calistoga Pharmaceuticals Garners $40,000,000 Series C Funding

  • Feed Type
  • Date
    6/30/2010
  • Company Name
    Calistoga Pharmaceuticals
  • Mailing Address
    2101 – 4th Avenue Seattle, WA 98121
  • Company Description
    Calistoga Pharmaceuticals, is developing a drug candidate acquired from Icos that has potential to treat various forms of cancer, according to the company.

    Icos, maker of the impotence drug Cialis, was acquired by its longtime marketing partner, pharmaceutical giant Eli Lilly & Co. (NYSE: LLY), in January, 2007 in a $2.3 billion deal.

  • Website
    http://www.calistogapharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $40,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The funds will be used to advance Calistoga Pharmaceuticals’ drug development pipeline of isoform-selective PI3K inhibitors. CAL-101, an oral, delta selective PI3K inhibitor, is currently being evaluated as a single agent in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (iNHL), mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) and in combination with rituximab or bendamustine in patients with relapsed or refractory iNHL or CLL.
  • M&A Terms
  • Venture Investor
    Alta Partners
  • Venture Investor
    Three Arch Partners
  • Venture Investor
    Frazier Healthcare Ventures
  • Venture Investor
    Amgen Ventures
  • Venture Investor
    Latterell Venture Partners